| bibliographicCitation |
Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Matsuzaki S, Yamazaki S, Ikeda K, Hara T, Kanetaka T, Kizawa T, Kikuchi M, Hara R, Fujii K, Takahashi M, Sonoda K, Yoshihashi T, Imagawa T, Yamazaki K, Ebato T, Oana S, Murase A, Sakaki S, Fujimoto T, Saito Y, Shirai R, Takeuchi I, Naoi K, Kenmotsu Y, Goto C, Kise H, Okada S, Kishimoto S, Oba U, Ozawa S, Seki M, Odagiri T, Shiono J, Nagumo K, Kimura M, Yoshibayashi M, Horita N, Tsuboi T, Matsubara T, Hara S, Ishii T, Hosokawa S, Kishi T, Fukazawa R, Ogawa S, Ohshima M, Fukunaga H, Kouzan H, Ichihara T, Hashimoto K, Tokunaga H, Suzuki H, Iwashima S, Hamahira K, Ishiguchi Y, Kajino M, Kishi K, Nagai N, Ito S, Ogino H, Amaya E, Doi H, Waki K, Shiraishi T, Iwai T, Sato T, Akimoto K, Soga T, Naito H, Aihara M, Fukuda Y, Imagawa K, Shiba T, Matsuki S, Miura M, Araki T, Furuyama H, Naito T, Miyamoto T. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan. The Journal of Pediatrics. 2018 Apr;195():115–120.e3. doi: 10.1016/j.jpeds.2017.10.013. |